Croda completed the acquisition of Avanti Polar Lipids for $260m.

Croda, a British speciality chemicals company, completed the acquisition of Avanti Polar Lipids, which manufactures and supplies lipid products, for $260m. "We have long admired the Avanti team for their deep scientific know-how and are already working together on high-potential commercial opportunities. With their exciting drug delivery technologies, Avanti is a market leader in a high growth niche of the health care market, serving over 3k customers globally. Bringing Avanti's best-in-class expertise into Croda also significantly enhances our presence across the pharma product lifecycle, including early stage R&D, clinical trials, analysis and formulation. I am confident that Avanti will prove transformative to the capabilities and performance of our Life Sciences sector," Steve Foots, Croda CEO.